STAAR Surgical Company Stock

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
46.39 USD -0.81% Intraday chart for STAAR Surgical Company -6.83% +48.64%
Sales 2024 * 339M Sales 2025 * 394M Capitalization 2.27B
Net income 2024 * - Net income 2025 * 26M EV / Sales 2024 * 5.83 x
Net cash position 2024 * 292M Net cash position 2025 * 313M EV / Sales 2025 * 4.95 x
P/E ratio 2024 *
2,577 x
P/E ratio 2025 *
102 x
Employees 1,057
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.81%
1 week-6.83%
Current month+21.19%
1 month+20.27%
3 months+59.80%
6 months+8.82%
Current year+48.64%
More quotes
1 week
45.51
Extreme 45.5072
50.00
1 month
35.12
Extreme 35.12
52.68
Current year
26.66
Extreme 26.6554
52.68
1 year
26.66
Extreme 26.6554
73.13
3 years
26.66
Extreme 26.6554
163.08
5 years
21.70
Extreme 21.7001
163.08
10 years
4.84
Extreme 4.84
163.08
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 20-05-31
Director of Finance/CFO 51 20-07-05
Chief Operating Officer - 23-04-23
Members of the board TitleAgeSince
Director/Board Member 59 15-12-31
Director/Board Member 55 22-06-15
Chief Executive Officer 68 20-05-31
More insiders
Date Price Change Volume
24-04-19 46.39 -0.81% 396,851
24-04-18 46.77 +0.93% 380,627
24-04-17 46.34 -0.60% 325,200
24-04-16 46.62 +0.87% 601,290
24-04-15 46.22 -7.17% 735,634

Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT

More quotes
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
46.77 USD
Average target price
49.17 USD
Spread / Average Target
+5.12%
Consensus